Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 12.89% year-over-year to $7.3 billion; the TTM figure through Mar 2026 stood at $7.3 billion (up 12.89% YoY), while the FY2025 annual figure was $7.3 billion, up 6.56% from the prior year.
• Total Non-Current Liabilities was $7.3 billion for Q1 2026 at Regeneron Pharmaceuticals, roughly flat from $7.3 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $7.3 billion in Q3 2025 to a low of $5.6 billion in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $6.5 billion across 5 years, with a median of $6.5 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities climbed 27.92% in 2023, then decreased 8.91% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $5.9 billion in 2022, then increased by 5.76% to $6.3 billion in 2023, then increased by 9.3% to $6.8 billion in 2024, then increased by 6.56% to $7.3 billion in 2025, then grew by 0.49% to $7.3 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.